tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics
PremiumRatingsSustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics
2d ago
Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
Premium
The Fly
Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
2d ago
Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion
Premium
Ratings
Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion
2M ago
Cito trims Travere target, opens ‘upside 90-day catalyst watch’
PremiumThe FlyCito trims Travere target, opens ‘upside 90-day catalyst watch’
2M ago
Buy Rating for Travere Therapeutics Amid Filspari’s FDA Review and Market Potential
Premium
Ratings
Buy Rating for Travere Therapeutics Amid Filspari’s FDA Review and Market Potential
3M ago
Travere Therapeutics Holds Annual Meeting, Elects Directors
Premium
Company Announcements
Travere Therapeutics Holds Annual Meeting, Elects Directors
3M ago
Closing Bell Movers: Applied Materials down over 5% after Q2 results
PremiumThe FlyClosing Bell Movers: Applied Materials down over 5% after Q2 results
3M ago
Travere Therapeutics’ FDA Acceptance for FILSPARI Application
Premium
Company Announcements
Travere Therapeutics’ FDA Acceptance for FILSPARI Application
3M ago
Travere Therapeutics announces FDA acceptance of sNDA for Filspari
Premium
The Fly
Travere Therapeutics announces FDA acceptance of sNDA for Filspari
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100